We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
- Authors
Szarvas, Tibor
- Abstract
This article discusses the use of immune checkpoint inhibition (ICI) as a promising therapeutic approach for advanced bladder cancer. The article highlights the availability of atezolizumab and pembrolizumab as second-line treatments for urothelial carcinoma (UC) that has progressed after chemotherapy, with high objective response rates and durable effects. It also mentions the approval of avelumab as a maintenance therapy and enfortumab-vedotin as a third-line treatment. The article emphasizes the need for predicting the efficacy of ICI and discusses a recent study that identified two gene expression-based immunophenotypes, which showed prognostic and potentially predictive value for ICI response. The study contributes to the growing body of gene expression-based research in bladder cancer treatment.
- Subjects
BLADDER cancer; EDITORIAL writing; IMMUNE checkpoint inhibitors; IMMUNOTHERAPY; THERAPEUTICS; TRANSITIONAL cell carcinoma
- Publication
International Journal of Urology, 2023, Vol 30, Issue 12, p1132
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.15296